| Systematic (IUPAC) name | |
|---|---|
| (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | oral |
| Identifiers | |
| CAS number | 207844-01-7 |
| ATC code | A10BX08 |
| PubChem | CID 121891 |
| DrugBank | DB01252 |
| ChemSpider | 108739 |
| UNII | D86I0XLB13 |
| KEGG | D01854 |
| ChEMBL | CHEMBL471498 |
| Chemical data | |
| Formula | C19H25NO3 |
| Mol. mass | 315.41 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.[1]
Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
|
Contents
|
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.
Mitiglinide is delivered in tablet form.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)